Idera Pharmaceuticals, Inc.
IDRA · NASDAQ
3/31/2023 | 12/31/2022 | 9/30/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | -0.00 | 0.00 | -0.00 |
| FCF Yield | -311,206.90% | -1,158.65% | -272.48% | -246.46% |
| EV / EBITDA | 0.08 | 0.94 | 2.77 | 4.26 |
| Quality | ||||
| ROIC | -33.45% | -11.36% | -3.73% | -24.82% |
| Gross Margin | 0.00% | 5,887.76% | -5,687.76% | 0.00% |
| Cash Conversion Ratio | 0.45 | 1.23 | 1.03 | 0.66 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | – | -100.00% |
| Free Cash Flow Growth | 25.39% | -312.88% | 9.28% | 22.83% |
| Safety | ||||
| Net Debt / EBITDA | 0.08 | 1.04 | 2.90 | 4.53 |
| Interest Coverage | 111.39 | -194.81 | -84.03 | -127.74 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -7,894.00 | 3,392.79 | 0.00 |